Gan & Lee Pharmaceuticals
SSE:603087

Watchlist Manager
Gan & Lee Pharmaceuticals Logo
Gan & Lee Pharmaceuticals
SSE:603087
Watchlist
Price: 44.65 CNY 0.86% Market Closed
Market Cap: 26.4B CNY
Have any thoughts about
Gan & Lee Pharmaceuticals?
Write Note

Intrinsic Value

The intrinsic value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is 45.32 CNY. Compared to the current market price of 44.65 CNY, Gan & Lee Pharmaceuticals is Undervalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
45.32 CNY
Undervaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Gan & Lee Pharmaceuticals

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for Gan & Lee Pharmaceuticals cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about Gan & Lee Pharmaceuticals?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Gan & Lee Pharmaceuticals

Provide an overview of the primary business activities
of Gan & Lee Pharmaceuticals.

What unique competitive advantages
does Gan & Lee Pharmaceuticals hold over its rivals?

What risks and challenges
does Gan & Lee Pharmaceuticals face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Gan & Lee Pharmaceuticals.

Provide P/S
for Gan & Lee Pharmaceuticals.

Provide P/E
for Gan & Lee Pharmaceuticals.

Provide P/OCF
for Gan & Lee Pharmaceuticals.

Provide P/FCFE
for Gan & Lee Pharmaceuticals.

Provide P/B
for Gan & Lee Pharmaceuticals.

Provide EV/S
for Gan & Lee Pharmaceuticals.

Provide EV/GP
for Gan & Lee Pharmaceuticals.

Provide EV/EBITDA
for Gan & Lee Pharmaceuticals.

Provide EV/EBIT
for Gan & Lee Pharmaceuticals.

Provide EV/OCF
for Gan & Lee Pharmaceuticals.

Provide EV/FCFF
for Gan & Lee Pharmaceuticals.

Provide EV/IC
for Gan & Lee Pharmaceuticals.

Show me price targets
for Gan & Lee Pharmaceuticals made by professional analysts.

What are the Revenue projections
for Gan & Lee Pharmaceuticals?

How accurate were the past Revenue estimates
for Gan & Lee Pharmaceuticals?

What are the Net Income projections
for Gan & Lee Pharmaceuticals?

How accurate were the past Net Income estimates
for Gan & Lee Pharmaceuticals?

What are the EPS projections
for Gan & Lee Pharmaceuticals?

How accurate were the past EPS estimates
for Gan & Lee Pharmaceuticals?

What are the EBIT projections
for Gan & Lee Pharmaceuticals?

How accurate were the past EBIT estimates
for Gan & Lee Pharmaceuticals?

Compare the revenue forecasts
for Gan & Lee Pharmaceuticals with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Gan & Lee Pharmaceuticals and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Gan & Lee Pharmaceuticals against its competitors.

Analyze the profit margins
(gross, operating, and net) of Gan & Lee Pharmaceuticals compared to its peers.

Compare the P/E ratios
of Gan & Lee Pharmaceuticals against its peers.

Discuss the investment returns and shareholder value creation
comparing Gan & Lee Pharmaceuticals with its peers.

Analyze the financial leverage
of Gan & Lee Pharmaceuticals compared to its main competitors.

Show all profitability ratios
for Gan & Lee Pharmaceuticals.

Provide ROE
for Gan & Lee Pharmaceuticals.

Provide ROA
for Gan & Lee Pharmaceuticals.

Provide ROIC
for Gan & Lee Pharmaceuticals.

Provide ROCE
for Gan & Lee Pharmaceuticals.

Provide Gross Margin
for Gan & Lee Pharmaceuticals.

Provide Operating Margin
for Gan & Lee Pharmaceuticals.

Provide Net Margin
for Gan & Lee Pharmaceuticals.

Provide FCF Margin
for Gan & Lee Pharmaceuticals.

Show all solvency ratios
for Gan & Lee Pharmaceuticals.

Provide D/E Ratio
for Gan & Lee Pharmaceuticals.

Provide D/A Ratio
for Gan & Lee Pharmaceuticals.

Provide Interest Coverage Ratio
for Gan & Lee Pharmaceuticals.

Provide Altman Z-Score Ratio
for Gan & Lee Pharmaceuticals.

Provide Quick Ratio
for Gan & Lee Pharmaceuticals.

Provide Current Ratio
for Gan & Lee Pharmaceuticals.

Provide Cash Ratio
for Gan & Lee Pharmaceuticals.

What is the historical Revenue growth
over the last 5 years for Gan & Lee Pharmaceuticals?

What is the historical Net Income growth
over the last 5 years for Gan & Lee Pharmaceuticals?

What is the current Free Cash Flow
of Gan & Lee Pharmaceuticals?

Discuss the annual earnings per share (EPS)
trend over the past five years for Gan & Lee Pharmaceuticals.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gan & Lee Pharmaceuticals

Current Assets 6.3B
Cash & Short-Term Investments 2B
Receivables 394.6m
Other Current Assets 4B
Non-Current Assets 5.6B
Long-Term Investments 439.7m
PP&E 3.9B
Intangibles 1.1B
Other Non-Current Assets 177.1m
Current Liabilities 763.7m
Accounts Payable 96.3m
Accrued Liabilities 137.3m
Other Current Liabilities 530.1m
Non-Current Liabilities 211.8m
Long-Term Debt 3.8m
Other Non-Current Liabilities 208m
Efficiency

Earnings Waterfall
Gan & Lee Pharmaceuticals

Revenue
2.7B CNY
Cost of Revenue
-750.1m CNY
Gross Profit
1.9B CNY
Operating Expenses
-1.7B CNY
Operating Income
213.5m CNY
Other Expenses
291.3m CNY
Net Income
504.8m CNY

Free Cash Flow Analysis
Gan & Lee Pharmaceuticals

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

Gan & Lee Pharmaceuticals's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
Positive Net Income
45/100
Profitability
Score

Gan & Lee Pharmaceuticals's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Gan & Lee Pharmaceuticals's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
87/100
Solvency
Score

Gan & Lee Pharmaceuticals's solvency score is 87/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Gan & Lee Pharmaceuticals

Wall Street analysts forecast Gan & Lee Pharmaceuticals stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Gan & Lee Pharmaceuticals is 69.36 CNY with a low forecast of 68.68 CNY and a high forecast of 71.4 CNY.

Lowest
Price Target
68.68 CNY
54% Upside
Average
Price Target
69.36 CNY
55% Upside
Highest
Price Target
71.4 CNY
60% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for Gan & Lee Pharmaceuticals?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for Gan & Lee Pharmaceuticals is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Gan & Lee Pharmaceuticals Logo
Gan & Lee Pharmaceuticals

Country

China

Industry

Biotechnology

Market Cap

26.8B CNY

Dividend Yield

0%

Description

Gan & Lee Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of recombinant insulin analogue raw materials and injections. The company is headquartered in Beijing, Beijing and currently employs 3,278 full-time employees. The company went IPO on 2020-06-29. The firm's main products are insulin preparations and insulin dry powder, including Changxiulin recombinant insulin glargine injection and Suxiulin recombinant insulin lispro injection. The company is also involved in the development and sales of a type of insulin pen called Xiulin Pen and the components. The firm provides early-stage franchising services by authorizing other companies to sell its insulin injections. The firm sells its products to both domestic and international markets, including Mexico and the Middle East.

Contact

BEIJING
Beijing
No.8, Fengxi 1st Road, Huoxian Town South, Tongzhou District
+861080593699
www.ganlee.com

IPO

2020-06-29

Employees

3 278

Officers

Founder & Chairman
Mr. Gan Zhongru
GM & Director
Mr. Kai Du
CFO & Deputy GM
Mr. Cheng Sun
Deputy GM & Director
Mr. Weiqiang Song
Secretary
Ms. Rong Zou
Deputy General Manager
Mr. Zhi Li

See Also

Discover More
What is the Intrinsic Value of one Gan & Lee Pharmaceuticals stock?

The intrinsic value of one Gan & Lee Pharmaceuticals stock under the Base Case scenario is 45.32 CNY.

Is Gan & Lee Pharmaceuticals stock undervalued or overvalued?

Compared to the current market price of 44.65 CNY, Gan & Lee Pharmaceuticals is Undervalued by 1%.

Back to Top